Trial Profile
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Ravulizumab (Primary) ; Eculizumab
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Registrational; Therapeutic Use
- Acronyms Study 302
- Sponsors Alexion AstraZeneca Rare Disease
- 15 Jun 2023 Results assessing clinical trial and real-world prevalence of csEVH in patients with PNH who were clinically stable on C5itreatment, and real-world physician-reported disease control and patient QoL, and physician- and patient-reported treatment satisfaction presented at the 28th Congress of the European Haematology Association.
- 15 Jun 2023 Results of clinical efficacy and safety of ravulizumab maintenance treatment for up to 4 years in complement inhibitor-experienced patients with PNH, presented at the 28th Congress of the European Haematology Association
- 01 Sep 2022 Results assessing long-term outcomes from two clinical studies (Study 301 and Study 302) from 27 weeks to two years published in the European Journal of Haematology